Protein aggregation and neurodegenerative disease (original) (raw)

• Taylor, J.P., Hardy, J. & Fischbeck, K.H. Toxic proteins in neurodegenerative disease. Science 296, 1991–1995 (2002).
  Article CAS PubMed Google Scholar
• Bates, G. Huntingtin aggregation and toxicity in Huntington's disease. Lancet 361, 1642–1644 (2003).
  Article CAS PubMed Google Scholar
• Caughey, B. & Lansbury, P.T. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu. Rev. Neurosci. 26, 267–298 (2003).
  Article CAS PubMed Google Scholar
• Berke, S.J. & Paulson, H.L. Protein aggregation and the ubiquitin proteasome pathway: gaining the UPPer hand on neurodegeneration. Curr. Opin. Genet. Dev. 13, 253–261 (2003).
  Article CAS PubMed Google Scholar
• Ross, C.A. & Pickart, C. The ubiquitin-proteasome pathway in Parkinson's and other neurodegenerative diseases. Trends Cell Biol. (2004).
• Nussbaum, R.L. & Ellis, C.E. Alzheimer's disease and Parkinson's disease. N. Engl. J. Med. 348, 1356–1364 (2003).
  Article CAS PubMed Google Scholar
• Wong, P.C., Cai, H., Borchelt, D.R. & Price, D.L. Genetically engineered mouse models of neurodegenerative diseases. Nat. Neurosci. 5, 633–639 (2002).
  Article CAS PubMed Google Scholar
• Ross, C.A. When more is less: pathogenesis of glutamine repeat neurodegenerative diseases. Neuron 15, 493–496 (1995).
  Article CAS PubMed Google Scholar
• Selkoe, D.J. Folding proteins in fatal ways. Nature 426, 900–904 (2003).
  Article CAS PubMed Google Scholar
• Davies, S.W. et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90, 537–548 (1997).
  Article CAS PubMed Google Scholar
• Scherzinger, E. et al. Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington's disease pathology. Proc. Natl. Acad. Sci. USA 96, 4604–4609 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Vonsattel, J.P. et al. Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol. 44, 559–577 (1985).
  Article CAS PubMed Google Scholar
• Kuemmerle, S. et al. Huntington aggregates may not predict neuronal death in Huntington's disease. Ann. Neurol. 46, 842–849 (1999).
  Article CAS PubMed Google Scholar
• Gutekunst, C.A. et al. Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J. Neurosci. 19, 2522–2534 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Becher, M.W. et al. Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat length. Neurobiol. Dis. 4, 387–397 (1998).
  Article CAS PubMed Google Scholar
• Myers, R.H. et al. Clinical and neuropathologic assessment of severity in Huntington disease. Neurology 38, 341–347 (1988).
  Article CAS PubMed Google Scholar
• Venkatraman, P., Wetzel, R., Tanaka, M., Nukina, N. & Goldberg, A.L. Eukaryotic proteasomes cannot digest polyglutamine sequences and release them during degradation of polyglutamine-containing proteins. Mol. Cell 14, 95–104 (2004).
  Article CAS PubMed Google Scholar
• Huang, C.C. et al. Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins. Somat. Cell Mol. Genet. 24, 217–233 (1998).
  Article CAS PubMed Google Scholar
• Kazantsev, A., Preisinger, E., Dranovsky, A., Goldgaber, D. & Housman, D. Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells. Proc. Natl. Acad. Sci. USA 96, 11404–11409 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Margolis, R.L. & Ross, C.A. Expansion explosion: new clues to the pathogenesis of repeat expansion neurodegenerative diseases. Trends Mol. Med. 7, 479–482 (2001).
  Article CAS PubMed Google Scholar
• Orr, H.T. & Zoghbi, H.Y. SCA1 molecular genetics: a history of a 13 year collaboration against glutamines. Hum. Mol. Genet. 10, 2307–2311 (2001).
  Article CAS PubMed Google Scholar
• Sen, S., Dash, D., Pasha, S. & Brahmachari, S.K. Role of histidine interruption in mitigating the pathological effects of long polyglutamine stretches in SCA1: a molecular approach. Protein Sci. 12, 953–962 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Selkoe, D.J. Alzheimer's disease is a synaptic failure. Science 298, 789–791 (2002).
  Article CAS PubMed Google Scholar
• Hardy, J. & Selkoe, D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353–356 (2002).
  Article CAS PubMed Google Scholar
• Serpell, L.C. & Smith, J.M. Direct visualisation of the β-sheet structure of synthetic Alzheimer's amyloid. J. Mol. Biol. 299, 225–231 (2000).
  Article CAS PubMed Google Scholar
• Esler, W.P. & Wolfe, M.S. A portrait of Alzheimer secretases—new features and familiar faces. Science 293, 1449–1454 (2001).
  Article CAS PubMed Google Scholar
• Citron, M. Alzheimer's disease: treatments in discovery and development. Nat. Neurosci. 5 (suppl.), 1055–1057 (2002).
  Article CAS PubMed Google Scholar
• Goedert, M. Tau protein and neurodegeneration. Semin. Cell Dev. Biol. 15, 45–49 (2004).
  Article CAS PubMed Google Scholar
• Ingram, E.M. & Spillantini, M.G. Tau gene mutations: dissecting the pathogenesis of FTDP–17. Trends Mol. Med. 8, 555–562 (2002).
  Article CAS PubMed Google Scholar
• Forno, L.S. Neuropathology of Parkinson's disease. J. Neuropathol. Exp. Neurol. 55, 259–272 (1996).
  Article CAS PubMed Google Scholar
• Dawson, T.M. & Dawson, V.L. Rare genetic mutations shed light on the pathogenesis of Parkinson disease. J. Clin. Invest 111, 145–151 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Valente, E.M. et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304, 1158–1160 (2004).
  Article CAS PubMed Google Scholar
• Cleveland, D.W. & Rothstein, J.D. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat. Rev. Neurosci. 2, 806–819 (2001).
  Article CAS PubMed Google Scholar
• Bruijn, L.I. et al. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 281, 1851–1854 (1998).
  Article CAS PubMed Google Scholar
• Rakhit, R. et al. Oxidation-induced misfolding and aggregation of superoxide dismutase and its implications for amyotrophic lateral sclerosis. J. Biol. Chem. 277, 47551–47556 (2002).
  Article CAS PubMed Google Scholar
• Prusiner, S.B. Shattuck lecture—neurodegenerative diseases and prions. N. Engl. J. Med. 344, 1516–1526 (2001).
  Article CAS PubMed Google Scholar
• Lindquist, S., Krobitsch, S., Li, L. & Sondheimer, N. Investigating protein conformation-based inheritance and disease in yeast. Phil. Trans. R. Soc. Lond. B 356, 169–176 (2001).
  Article CAS Google Scholar
• Scheibel, T., Bloom, J. & Lindquist, S.L. The elongation of yeast prion fibers involves separable steps of association and conversion. Proc. Natl. Acad. Sci. USA 101, 2287–2292 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Ma, J., Wollmann, R. & Lindquist, S. Neurotoxicity and neurodegeneration when PrP accumulates in the cytosol. Science 298, 1781–1785 (2002).
  Article CAS PubMed Google Scholar
• Ma, J. & Lindquist, S. Conversion of PrP to a self-perpetuating PrPSc-like conformation in the cytosol. Science 298, 1785–1788 (2002).
  Article CAS PubMed Google Scholar
• Eanes, E.D. & Glenner, G.G. X-ray diffraction studies on amyloid filaments. J. Histochem. Cytochem. 16, 673–677 (1968).
  Article CAS PubMed Google Scholar
• Sunde, M. & Blake, C.C. From the globular to the fibrous state: protein structure and structural conversion in amyloid formation. Q. Rev. Biophys. 31, 1–39 (1998).
  Article CAS PubMed Google Scholar
• Benzinger, T.L. et al. Propagating structure of Alzheimer's β-amyloid(10–35) is parallel β-sheet with residues in exact register. Proc. Natl. Acad. Sci. USA 95, 13407–13412 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Tycko, R. Insights into the amyloid folding problem from solid-state NMR. Biochemistry 42, 3151–3159 (2003).
  Article CAS PubMed Google Scholar
• Torok, M. et al. Structural and dynamic features of Alzheimer's Aβ peptide in amyloid fibrils studied by site-directed spin labeling. J. Biol. Chem. 277, 40810–40815 (2002).
  Article PubMed CAS Google Scholar
• Der-Sarkissian, A., Jao, C.C., Chen, J. & Langen, R. Structural organization of α-synuclein fibrils studied by site-directed spin labeling. J. Biol. Chem. 278, 37530–37535 (2003).
  Article CAS PubMed Google Scholar
• Benzinger, T.L. et al. Two-dimensional structure of β-amyloid(10–35) fibrils. Biochemistry 39, 3491–3499 (2000).
  Article CAS PubMed Google Scholar
• Balbach, J.J. et al. Amyloid fibril formation by Aβ16–22, a seven-residue fragment of the Alzheimer's β-amyloid peptide, and structural characterization by solid state NMR. Biochemistry 39, 13748–13759 (2000).
  Article CAS PubMed Google Scholar
• Williams, A.D. et al. Mapping Aβ amyloid fibril secondary structure using scanning proline mutagenesis. J. Mol. Biol. 335, 833–842 (2004).
  Article CAS PubMed Google Scholar
• Thakur, A.K. & Wetzel, R. Mutational analysis of the structural organization of polyglutamine aggregates. Proc. Natl. Acad. Sci. USA 99, 17014–17019 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Ross, C.A., Poirier, M.A., Wanker, E.E. & Amzel, M. Polyglutamine fibrillogenesis: the pathway unfolds. Proc. Natl. Acad. Sci. USA 100, 1–3 (2003).
  Article CAS PubMed Google Scholar
• Chen, S., Berthelier, V., Hamilton, J.B., O'Nuallain, B. & Wetzel, R. Amyloid-like features of polyglutamine aggregates and their assembly kinetics. Biochemistry 41, 7391–7399 (2002).
  Article CAS PubMed Google Scholar
• O'Nuallain, B. & Wetzel, R. Conformational Abs recognizing a generic amyloid fibril epitope. Proc. Natl. Acad. Sci. USA 99, 1485–1490 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Uversky, V.N. Protein folding revisited. A polypeptide chain at the folding-misfolding-nonfolding cross-roads: which way to go? Cell Mol. Life Sci. 60, 1852–1871 (2003).
  Article CAS PubMed Google Scholar
• Clarke, G. et al. A one-hit model of cell death in inherited neuronal degenerations. Nature 406, 195–199 (2000).
  Article CAS PubMed Google Scholar
• Dobson, C.M. Principles of protein folding, misfolding and aggregation. Semin. Cell Dev. Biol. 15, 3–16 (2004).
  Article CAS PubMed Google Scholar
• Sacchettini, J.C. & Kelly, J.W. Therapeutic strategies for human amyloid diseases. Nat. Rev. Drug Discov. 1, 267–275 (2002).
  Article CAS PubMed Google Scholar
• Lansbury, P.T., Jr. Structural neurology: are seeds at the root of neuronal degeneration? Neuron 19, 1151–1154 (1997).
  Article CAS PubMed Google Scholar
• Soto, C. Unfolding the role of protein misfolding in neurodegenerative diseases. Nat. Rev. Neurosci. 4, 49–60 (2003).
  Article CAS PubMed Google Scholar
• Singleton, A.B. et al. α-Synuclein locus triplication causes Parkinson's disease. Science 302, 841 (2003).
  Article CAS PubMed Google Scholar
• Singleton, A., Myers, A. & Hardy, J. The law of mass action applied to neurodegenerative disease: a hypothesis concerning the etiology and pathogenesis of complex diseases. Hum. Mol. Genet. 13 (special no 1), R123–R126 (2004).
  Article CAS PubMed Google Scholar
• Conway, K.A., Rochet, J.C., Bieganski, R.M. & Lansbury, P.T., Jr. Kinetic stabilization of the α-synuclein protofibril by a dopamine-α-synuclein adduct. Science 294, 1346–1349 (2001).
  Article CAS PubMed Google Scholar
• Giasson, B.I. et al. Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synucleinopathy lesions. Science 290, 985–989 (2000).
  Article CAS PubMed Google Scholar
• Iwatsubo, T. et al. Purification and characterization of Lewy bodies from the brains of patients with diffuse Lewy body disease. Am. J. Pathol. 148, 1517–1529 (1996).
  CAS PubMed PubMed Central Google Scholar
• Iwatsubo, T. Aggregation of α-synuclein in the pathogenesis of Parkinson's disease. J. Neurol. 250 (suppl. 3), III11–III14 (2003).
  PubMed Google Scholar
• Okochi, M. et al. Constitutive phosphorylation of the Parkinson's disease associated α-synuclein. J. Biol. Chem. 275, 390–397 (2000).
  Article CAS PubMed Google Scholar
• Spillantini, M.G. et al. α-synuclein in Lewy bodies. Nature 388, 839–840 (1997).
  Article CAS PubMed Google Scholar
• Emamian, E.S. et al. Serine 776 of ataxin-1 is critical for polyglutamine-induced disease in SCA1 transgenic mice. Neuron 38, 375–387 (2003).
  Article CAS PubMed Google Scholar
• Steffan, J.S. et al. Modification of Huntingtin and Huntington's disease pathology. Science 304, 100–104 (2004).
  Article CAS PubMed Google Scholar
• DiFiglia, M. et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277, 1990–1993 (1997).
  Article CAS PubMed Google Scholar
• Saudou, F., Finkbeiner, S., Devys, D. & Greenberg, M.E. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95, 55–66 (1998).
  Article CAS PubMed Google Scholar
• Peters, M.F. et al. Nuclear targeting of mutant Huntingtin increases toxicity. Mol. Cell Neurosci. 14, 121–128 (1999).
  Article CAS PubMed Google Scholar
• de Almeida, L.P., Ross, C.A., Zala, D., Aebischer, P. & Deglon, N. Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length. J. Neurosci. 22, 3473–3483 (2002).
  Article PubMed PubMed Central Google Scholar
• Wellington, C.L. et al. Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease. J. Neurosci. 22, 7862–7872 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Gafni, J. et al. Inhibition of calpain cleavage of Huntingtin reduces toxicity: accumulation of calpain/caspase fragments in the nucleus. J. Biol. Chem. 279, 21211–21220 (2004).
  Article CAS Google Scholar
• Lunkes, A. et al. Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions. Mol. Cell 10, 259–269 (2002).
  Article CAS PubMed Google Scholar
• Poirier, M.A. et al. Huntingtin spheroids and protofibrils as precursors in polyglutamine fibrilization. J. Biol. Chem. 277, 41032–41037 (2002).
  Article CAS PubMed Google Scholar
• Nucifora, F.C., Jr. et al. Nuclear localization of a non-caspase truncation product of atrophin-1, with an expanded polyglutamine repeat, increases cellular toxicity. J. Biol. Chem. 278, 13047–13055 (2003).
  Article CAS PubMed Google Scholar
• Lee, E.N. et al. Phthalocyanine tetrasulfonates affect the amyloid formation and cytotoxicity of α-synuclein. Biochemistry 43, 3704–3715 (2004).
  Article CAS PubMed Google Scholar
• Buxbaum, J.N. Diseases of protein conformation: what do in vitro experiments tell us about in vivo diseases? Trends Biochem. Sci. 28, 585–592 (2003).
  Article CAS PubMed Google Scholar
• Wetzel, R. Ideas of order for amyloid fibril structure. Structure (Camb) 10, 1031–1036 (2002).
  Article CAS Google Scholar
• Soreghan, B., Kosmoski, J. & Glabe, C. Surfactant properties of Alzheimer's Aβ peptides and the mechanism of amyloid aggregation. J. Biol. Chem. 269, 28551–28554 (1994).
  CAS PubMed Google Scholar
• Harper, J.D., Lieber, C.M. & Lansbury, P.T., Jr. Atomic force microscopic imaging of seeded fibril formation and fibril branching by the Alzheimer's disease amyloid-β protein. Chem. Biol. 4, 951–959 (1997).
  Article CAS PubMed Google Scholar
• Lambert, M.P. et al. Diffusible, nonfibrillar ligands derived from Aβ1–42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. USA 95, 6448–6453 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Harper, J.D., Wong, S.S., Lieber, C.M. & Lansbury, P.T., Jr. Assembly of Aβ amyloid protofibrils: an in vitro model for a possible early event in Alzheimer's disease. Biochemistry 38, 8972–8980 (1999).
  Article CAS PubMed Google Scholar
• Harper, J.D. & Lansbury, P.T., Jr. Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu. Rev. Biochem. 66, 385–407 (1997).
  Article CAS PubMed Google Scholar
• Walsh, D.M., Lomakin, A., Benedek, G.B., Condron, M.M. & Teplow, D.B. Amyloid β-protein fibrillogenesis. Detection of a protofibrillar intermediate. J. Biol. Chem. 272, 22364–22372 (1997).
  Article CAS PubMed Google Scholar
• Klein, W.L., Krafft, G.A. & Finch, C.E. Targeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci. 24, 219–224 (2001).
  Article CAS PubMed Google Scholar
• Terry, R.D. et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 30, 572–580 (1991).
  Article CAS PubMed Google Scholar
• McLean, C.A. et al. Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46, 860–866 (1999).
  Article CAS PubMed Google Scholar
• Lue, L.F. et al. Soluble amyloid β peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol. 155, 853–862 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Walsh, D.M. et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535–539 (2002).
  Article CAS PubMed Google Scholar
• Volles, M.J. et al. Vesicle permeabilization by protofibrillar α-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40, 7812–7819 (2001).
  Article CAS PubMed Google Scholar
• Sharon, R. et al. The formation of highly soluble oligomers of α-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron 37, 583–595 (2003).
  Article CAS PubMed Google Scholar
• Chen, S., Berthelier, V., Yang, W. & Wetzel, R. Polyglutamine aggregation behavior in vitro supports a recruitment mechanism of cytotoxicity. J. Mol. Biol. 311, 173–182 (2001).
  Article CAS PubMed Google Scholar
• Sanchez, I., Mahlke, C. & Yuan, J. Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature 421, 373–379 (2003).
  Article CAS PubMed Google Scholar
• Nucifora, F.C., Jr. et al. Interference by huntingtin and atrophin-1 with CBP-mediated transcription leading to cellular toxicity. Science 291, 2423–2428 (2001).
  Article CAS PubMed Google Scholar
• Jiang, H., Nucifora, F.C., Jr., Ross, C.A. & DeFranco, D.B. Cell death triggered by polyglutamine-expanded huntingtin in a neuronal cell line is associated with degradation of CREB-binding protein. Hum. Mol. Genet. 12, 1–12 (2003).
  Article PubMed Google Scholar
• Bence, N.F., Sampat, R.M. & Kopito, R.R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292, 1552–1555 (2001).
  Article CAS PubMed Google Scholar
• Kayed, R. et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486–489 (2003).
  Article CAS PubMed Google Scholar
• McClellan, A.J. & Frydman, J. Molecular chaperones and the art of recognizing a lost cause. Nat. Cell Biol. 3, E51–E53 (2001).
  Article CAS PubMed Google Scholar
• Goldberg, A.L. Protein degradation and protection against misfolded or damaged proteins. Nature 426, 895–899 (2003).
  Article CAS PubMed Google Scholar
• Ciechanover, A. & Brundin, P. The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. Neuron 40, 427–446 (2003).
  Article CAS PubMed Google Scholar
• Kopito, R.R. Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol. 10, 524–530 (2000).
  Article CAS PubMed Google Scholar
• Ravikumar, B. et al. Inhibitor of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat. Genet. 36, 585–595 (2004).
  Article CAS PubMed Google Scholar
• Tanaka, M. et al. Aggresomes formed by α-synuclein and synphilin-1 are cytoprotective. J. Biol. Chem. 279, 4625–4631 (2004).
  Article CAS PubMed Google Scholar
• Verhoef, L.G., Lindsten, K., Masucci, M.G. & Dantuma, N.P. Aggregate formation inhibits proteasomal degradation of polyglutamine proteins. Hum. Mol. Genet. 11, 2689–2700 (2002).
  Article CAS PubMed Google Scholar
• Winklhofer, K.F., Reintjes, A., Hoener, M.C., Voellmy, R. & Tatzelt, J. Geldanamycin restores a defective heat shock response in vivo. J. Biol. Chem. 276, 45160–45167 (2001).
  Article CAS PubMed Google Scholar
• Piper, P.W. The Hsp90 chaperone as a promising drug target. Curr. Opin. Investig. Drugs 2, 1606–1610 (2001).
  CAS PubMed Google Scholar
• Yamamoto, A., Lucas, J.J. & Hen, R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 101, 57–66 (2000).
  Article CAS PubMed Google Scholar
• Davidson, B.L. & Paulson, H.L. Molecular medicine for the brain: silencing of disease genes with RNA interference. Lancet Neurol. 3, 145–149 (2004).
  Article CAS PubMed Google Scholar
• Miller, V.M. et al. Allele-specific silencing of dominant disease genes. Proc. Natl. Acad. Sci. USA 100, 7195–7200 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Monsonego, A. & Weiner, H.L. Immunotherapeutic approaches to Alzheimer's disease. Science 302, 834–838 (2003).
  Article CAS PubMed Google Scholar
• Mattson, M.P. & Chan, S.L. Good and bad amyloid antibodies. Science 301, 1847–1849 (2003).
  Article CAS PubMed Google Scholar
• Weiner, H.L. & Selkoe, D.J. Inflammation and therapeutic vaccination in CNS diseases. Nature 420, 879–884 (2002).
  Article CAS PubMed Google Scholar
• Tanaka, M. et al. Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat. Med. 10, 148–154 (2004).
  Article CAS PubMed Google Scholar
• Bohrmann, B. et al. Self-assembly of β-amyloid 42 is retarded by small molecular ligands at the stage of structural intermediates. J. Struct. Biol. 130, 232–246 (2000).
  Article CAS PubMed Google Scholar
• Wood, S.J., MacKenzie, L., Maleeff, B., Hurle, M.R. & Wetzel, R. Selective inhibition of Aβ fibril formation. J. Biol. Chem. 271, 4086–4092 (1996).
  Article CAS PubMed Google Scholar
• Reixach, N., Crooks, E., Ostresh, J.M., Houghten, R.A. & Blondelle, S.E. Inhibition of β-amyloid-induced neurotoxicity by imidazopyridoindoles derived from a synthetic combinatorial library. J. Struct. Biol. 130, 247–258 (2000).
  Article CAS PubMed Google Scholar
• May, B.C. et al. Potent inhibition of scrapie prion replication in cultured cells by bis-acridines. Proc. Natl. Acad. Sci. USA 100, 3416–3421 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Cordeiro, Y., Lima, L.M., Gomes, M.P., Foguel, D. & Silva, J.L. Modulation of prion protein oligomerization, aggregation, and β-sheet conversion by 4,4'-dianilino-1,1'-binaphthyl-5,5′-sulfonate (bis-ANS). J. Biol. Chem. 279, 5346–5352 (2004).
  Article CAS PubMed Google Scholar
• Heiser, V. et al. Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assay. Proc. Natl. Acad. Sci. USA 99, 16400–16406 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Pollitt, S.K. et al. A rapid cellular FRET assay of polyglutamine aggregation identifies a novel inhibitor. Neuron 40, 685–694 (2003).
  Article CAS PubMed Google Scholar
• John, V., Beck, J.P., Bienkowski, M.J., Sinha, S. & Heinrikson, R.L. Human β-secretase (BACE) and BACE inhibitors. J. Med. Chem. 46, 4625–4630 (2003).
  Article CAS PubMed Google Scholar
• Petkova, A.T. et al. A structural model for Alzheimer's β-amyloid fibrils based on experimental constraints from solid state NMR. Proc. Natl. Acad. Sci. USA 99, 16742–16747 (2002).
  Article CAS PubMed PubMed Central Google Scholar